• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Progyny Adds Pelvic Floor Therapy, Continuing to Close Gaps in Care Across Women's Health

    6/24/25 9:10:00 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care
    Get the next $PGNY alert in real time by email

    NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that it is adding pelvic floor therapy to its comprehensive offering of women's health and family building solutions. With the expansion of its network of specialty trained women's health providers, and the addition of digital therapy, the company is further deepening its commitment to increasing the accessibility of specialized, timely care across the spectrum from preconception and maternal health to midlife and menopause.

    One in three women experience pelvic floor issues, with one in five needing to undergo surgery to treat their pelvic floor disorder (UCM). While most commonly associated with postpartum care, pelvic floor complications impact women as early as young adulthood and span through menopause and later into life. When left untreated, not only can pelvic pain interfere with quality of life that can lead to reduced performance at work and absenteeism, but it can also result in avoidable health complications and increased downstream medical costs. For instance, conditions such as endometriosis and sexual dysfunction are linked to untreated pelvic health issues, which can lead to infertility.

    "This is another moment when Progyny is stepping up to help women identify and seek care for basic health needs that are going undiagnosed and untreated due to lack of education, lack of care access, and lack of the right benefits coverage," said Dr. Janet Choi, Progyny Chief Medical Officer. "By enabling access to specialty trained providers and offering educational support tools through a cost effective and comprehensive benefit, we are providing impactful clinical solutions as opposed to a ‘sweep it under the rug' approach to women's health."

    Virtual and In-Person Support Options for Treatment and Coaching

    Progyny members will have expanded access to both in-person and virtual care options. Through this integrated and multi-pronged approach, members will benefit from earlier interventions for pelvic conditions, reducing fragmentation, and helping avoid delays that could lead to higher acuity treatments, surgeries, or increased healthcare costs for employers. Urinary incontinence alone has been associated with costing the healthcare industry $20 billion a year (NIH).

    Progyny welcomes Origin and Hinge Health to its offering. With Origin, Progyny members can seamlessly access Origin's nationwide in-network pelvic floor physical therapy, both in-person and virtually. Origin provides evidence-based treatment for the full spectrum of pelvic health needs—from common concerns like leaky bladder, painful sex, and postpartum recovery, to more complex conditions including hysterectomy recovery, endometriosis, PCOS, and chronic pelvic pain. Origin's specialized physical therapists provide evidence-based care that addresses both physical and mental health through every stage of life, whether you're preparing for childbirth, recovering from surgery, or managing ongoing symptoms.

    "Origin has been leading the way in destigmatizing the shame that still exists around the biggest milestones in women's lives and working to make pelvic floor therapy part of the standard of care," said Carine Carmy, CEO & Co-Founder, Origin. "Whether it's postpartum recovery or painful sex in menopause, our goal is to make personalized, whole-body care accessible to women wherever they are in their health journey."

    With Hinge Health, members will receive digital care supported by physical therapists specializing in pelvic health and musculoskeletal (MSK) care. Each individual will follow a personalized plan with guided exercises targeting their unique symptoms – including but not limited to pelvic pain, a lack of pelvic strength or bladder control, and issues associated with menopause. By engaging regularly with these exercises, members build sustainable habits and make positive lifestyle adjustments that are proven to relieve symptoms and improve overall health.

    "By combining expert clinical care and advanced technology, we are removing barriers to care access and enabling individuals to experience better health outcomes," said Aaryn Pure, Chief Commercial Officer, Hinge Health. "Our comprehensive pelvic health program, now offered in conjunction with Progyny, will bring their members high-quality pelvic health support as part of their broader women's health experience."

    For more information on Progyny and its pelvic floor offering, visit www.progyny.com.

    About Progyny

    Progyny (NASDAQ:PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians.

    Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.

    Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.

    For Further Information, Please Contact:



    Media:

    Alexis Ford

    [email protected]

    Investors:

    James Hart

    [email protected]



    Primary Logo

    Get the next $PGNY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PGNY

    DatePrice TargetRatingAnalyst
    12/2/2024$17.00Overweight → Neutral
    Analyst
    11/13/2024$26.00 → $19.00Buy → Hold
    Truist
    9/19/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024$37.00 → $24.00Buy → Hold
    Canaccord Genuity
    8/7/2024$31.00 → $25.00Outperform → Market Perform
    Leerink Partners
    8/7/2024Buy → Neutral
    BTIG Research
    7/16/2024$36.00Mkt Outperform
    JMP Securities
    5/10/2024Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $PGNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Progyny downgraded by Analyst with a new price target

      Analyst downgraded Progyny from Overweight to Neutral and set a new price target of $17.00

      12/2/24 10:07:08 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny downgraded by Truist with a new price target

      Truist downgraded Progyny from Buy to Hold and set a new price target of $19.00 from $26.00 previously

      11/13/24 8:20:07 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny downgraded by JMP Securities

      JMP Securities downgraded Progyny from Mkt Outperform to Mkt Perform

      9/19/24 7:51:03 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Progyny Adds Pelvic Floor Therapy, Continuing to Close Gaps in Care Across Women's Health

      NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that it is adding pelvic floor therapy to its comprehensive offering of women's health and family building solutions. With the expansion of its network of specialty trained women's health providers, and the addition of digital therapy, the company is further deepening its commitment to increasing the accessibility of specialized, timely care across the spectrum from preconception and maternal health to midlife and menopause. One in three women experience pelvic floor issues, with one in five needing to undergo surgery to treat their pelv

      6/24/25 9:10:00 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Joins Amazon's Health Benefits Connector Program as First Women's Health and Family Building Solution

      NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced a new collaboration with Amazon's Health Benefits Connector to expand access to comprehensive women's health services. Through Amazon's Health Benefits Connector, eligible individuals can now seamlessly discover and enroll in Progyny benefits that are available to them through their employer or health plan. Progyny's high-touch, clinically integrated care model is used by over 530 employers and health plans across the U.S., supporting more than 6.7 million lives. The company's benefits span the full reproductive health continuum – includ

      6/10/25 9:02:11 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Adds Distinguished Healthcare Executive Elizabeth Bierbower to Board of Directors

      NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced the addition of healthcare veteran Elizabeth Bierbower to its Board of Directors. "As we continue to round out our board's experience, Elizabeth's extensive leadership with some of the largest health plans and deep financial expertise will be invaluable as we scale and innovate across the women's health and family building spectrum," said Pete Anevski, CEO of Progyny. "Her insights will support our strategy to deliver even more value to our members, clients, and shareholders as we expand our reach and impact." Bierbower brings more than

      5/29/25 9:03:40 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    SEC Filings

    See more
    • SEC Form 144 filed by Progyny Inc.

      144 - Progyny, Inc. (0001551306) (Subject)

      6/3/25 12:05:25 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Progyny, Inc. (0001551306) (Filer)

      5/28/25 4:37:32 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 10-Q filed by Progyny Inc.

      10-Q - Progyny, Inc. (0001551306) (Filer)

      5/9/25 4:31:42 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Leadership Updates

    Live Leadership Updates

    See more
    • Progyny Appoints Two Renowned Women's Health Experts to Medical Advisory Board

      NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced the appointment of Morehouse School of Medicine's Regional Dean for Seattle and Puget Sound's Dr. Gloria Richard-Davis – a double-board certified physician in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility, a fellow of the American College of Obstetricians & Gynecologists (FACOG), and a Menopause Society Certified Practitioner (MSCP) – and Columbia University's Dr. Whitney Booker – a double-board certified physician in Obstetrics and Gynecology and Maternal-Fetal Medicine – to its Medical Advisory Board. "As Pr

      5/14/25 9:05:48 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer

      NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del

      4/17/25 9:36:59 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Progyny Inc.

      SC 13G/A - Progyny, Inc. (0001551306) (Subject)

      12/6/24 10:11:35 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Progyny Inc.

      SC 13G/A - Progyny, Inc. (0001551306) (Subject)

      11/14/24 4:31:23 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Progyny Inc. (Amendment)

      SC 13G/A - Progyny, Inc. (0001551306) (Subject)

      2/14/24 6:29:49 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chairman Schlanger David J covered exercise/tax liability with 1,893 shares, decreasing direct ownership by 0.84% to 222,312 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      7/2/25 4:10:43 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • CHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 7,977 shares, decreasing direct ownership by 1% to 547,541 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      7/2/25 4:09:09 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Director Scott Cheryl sold $59,037 worth of shares (2,675 units at $22.07), decreasing direct ownership by 16% to 14,112 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      6/12/25 5:07:13 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chairman Schlanger David J bought $2,202,330 worth of shares (150,000 units at $14.68), increasing direct ownership by 192% to 228,269 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      12/26/24 5:35:03 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • CHIEF EXECUTIVE OFFICER Anevski Peter bought $3,034,084 worth of shares (209,500 units at $14.48), increasing direct ownership by 90% to 441,463 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      12/26/24 5:31:32 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Financials

    Live finance-specific insights

    See more
    • Progyny, Inc. Announces First Quarter 2025 Results

      Reports Record Revenue of $324.0 Million, Reflecting 16.5% GrowthRaises Full Year Guidance Due to Strong Start to the YearEarly Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2025 ("the first quarter of 2025") as compared to the three-month period ended March 31, 2024 ("the first quarter of 2024" or "the prior year period"). "We're pleased with the strong start to the year, highlighted by both our

      5/8/25 4:14:54 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Announces Details for Its First Quarter 2025 Results Report

      NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building, will report its financial results for the quarterly period ended March 31, 2025, after the close of the market on Thursday, May 8, 2025. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An audio repl

      4/24/25 2:49:33 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny, Inc. Announces Fourth Quarter 2024 Results

      Reports Quarterly Revenue of $298.4 Million, Reflecting 10.6% GrowthGenerated $52.2 Million of Quarterly Operating Cash FlowIssues Financial Guidance for 2025, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three- and twelve-month periods ended December 31, 2024 ("the fourth quarter of 2024" and "the full year", respectively) as compared to the three- and twelve-month periods ended December 31, 2023 ("the fourth quarter of 2023" and "the prior year period",

      2/27/25 4:01:22 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care